Media about us

06 December 2013

NovaMedica, Aptalis Sign Russian Distribution Pact

Contact Pharma

NovaMedica has signed a partnership agreement with Aptalis Pharma to develop and commercialize three of Aptalis' gastrointestinal products in Russia. The products include Pylera, indicated for the eradication of Helicobacter Pylori in patients with gastric or duodenal ulcer; Lacteol, a product derived from a human strain of Lactobacillus LB for use in patients with diarrhea; and Panzytrat, a formulation of pancreatic enzymes indicated for maldigestion due to exocrine pancreatic insufficiency related to cystic fibrosis, chronic pancreatitis, major pancreatic resection, gastric resection.  

17 October 2013

Kremlin seeks to monetise the field of science

Isabel Gorst, Financial Times

Change is coming to the 289-year-old Russian Academy of Sciences. Once famous for work that won it 18 Nobel Prizes and helped put the first man in space, the Academy has failed to keep up with the times.

23 September 2013

With full comfort

BIGRUSSIA, Svetlana Samodelova. Photo: Evgeny Dudin. Translated by: Jack Doughty

Garrett Johnston: Russian capital, brands, ideas and people can and must change the whole world for the better.

02 August 2013

RusnanoMedInvest invested in American technology for vision correction

Venture News

American venture Fund Domain Associates, venture investment company RusnanoMedInvest (RMI, affiliate of ROSNANO) and a group of co-investors invest $55M in the company ReVision Optics, Inc., which develops innovation medical technology for treatment of age-dependent visual acuity decrement.

31 July 2013

As ReVision Raises $55M, Domain’s Brian Dovey Assesses Rusnano Gambit

Bruce V. Bigelow, Xconomy

Almost 18 months ago, Domain Associates and the Russian state technology firm Rusnano agreed to jointly invest as much as $760 million in life sciences deals in the U.S. and Russia. Yesterday, the partners said they have completed their fifth deal—joining a $55 million equity round in ReVision Optics, a Lake Forest, CA-ophthalmic company.

30 July 2013

Rusnano Invests With U.S. Venture Fund

The Moscow Times

Rusnano subsidiary RusnanoMednvest and U.S. venture fund Domain Associates have joined a consortium investing $55 million in the U.S. firm ReVision Optics, which is developing technologies to treat age-related vision loss, Interfax reported.

30 July 2013

Domain, Rusnano invest in ReVision

BioCentury

Domain Associates and Rusnano, the state-funded $10 billion Russian fund, made their fifth investment under a 2012 investment partnership in Domain portfolio company ReVision Optics Inc. (Lake Forest, Calif.). 

30 July 2013

J&J buys into ReVision Optics' $55M financing round

Mark Hollmer, FierceMedicalDevices

ReVision Optics attracted an impressive $55 million in new equity financing from the likes of Johnson & Johnson ($JNJ) and a Russian investor group--a massive cash infusion that will advance its hydrogel eye implant designed to help reduce the need for reading glasses.

30 July 2013

New Russian company to build $85M plant

Eric Palmer, FiercePharmaManufacturing

NovaMedica was formed out of Domain Associates' partnership with RUSNANO.

29 July 2013

$85m Plant Demonstrates Russia's Commitment to Pharma 2020, says NovaMedica

Dan Stanton, In-Pharma Technologist.com

NovaMedica and the Russian Government are to build an $85m (€64m) facility as part of a joint venture encouraging local manufacturing, the company says.